Sotorasib

Major

Sotorasib Clindamycin ANTIROBE Explained Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Omeprazole Gastrobim Explained Reduced sotorasib exposure and anti-tumor activity Details Sotorasib Relugolix Orgovyx Explained Increased relugolix exposure Details Sotorasib Colchicine Colcrys Explained Increased exposure to P-gp substrate and risk of toxicity Details Sotorasib Abemaciclib Verzenio Explained Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Acalabrutinib Calquence Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Atogepant Qulipta Reduced atogepant exposure Details Sotorasib Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Sotorasib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Sotorasib Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Sotorasib Amlodipine Amvaz® Reduced amLODIPine exposure Details Sotorasib Axitinib Inlyta Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Sotorasib Bosutinib Bosulif Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Brigatinib Alunbrig Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Sotorasib Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Sotorasib Clindamycin Injection ANTIROBE Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Clindamycin Topical C/T/S® Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Clindamycin Vaginal Cleocin Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Cobimetinib Cotellic Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Cyclosporine Injection Atopica Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Cyclosporine Ophthalmic Cequa Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Sotorasib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Sotorasib Dasatinib Phyrago Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Dexlansoprazole Dexilant Reduced sotorasib exposure and anti-tumor activity Details Sotorasib Digoxin Cardoxin® Increased exposure to P-gp substrate and risk of toxicity Details Sotorasib Dihydroergotamine Injection DHE-45® Injection Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Dihydroergotamine Nasal Spray Migranal Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Docetaxel Beizray Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Docetaxel Injection Beizray Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Dofetilide Tikosyn Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Doravirine Pifeltro Reduced doravirine exposure and reduced efficacy of doravirine Details Sotorasib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Sotorasib Entrectinib Rozlytrek Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Sotorasib Esomeprazole Nexium Reduced sotorasib exposure and anti-tumor activity Details Sotorasib Esomeprazole Injection Nexium Reduced sotorasib exposure and anti-tumor activity Details Sotorasib Everolimus Afinitor Increased exposure to P-gp substrate and risk of toxicity Details Sotorasib Famotidine Calmicid Reduced sotorasib exposure and anti-tumor activity Details